

Community acquired *Burkholderia cepacia* sepsis in a patient with megaloblastic anemia: a case report and review of literature

M.A. Abraham, M. John, J. Abraham

Department of Medicine, Christian Medical College and Hospital, Ludhiana, India

ABSTRACT: *Burkholderia cepacia* complex (Bcc) is known to cause respiratory tract infections among patients with cystic fibrosis. *Burkholderia* infection is also seen in patients admitted in ICUs who are immunocompromised and results in lower respiratory tract infection, necrotizing pneumonia or septicemia. It is inherently resistant to many antibiotics like carboxypenicillins, polymyxin and aminoglycosides. In this case report, we present the case of a patient with Vitamin B12 deficiency who acquired *Burkholderia* infection from the community and presented with features of septic shock and generalized tonic-clonic seizures. Patients with Bcc infection can be treated by co-trimoxazole, meropenem, ceftazidime or piperacillin-tazobactam which can be given as monotherapy or as combination therapy along with other antimicrobial agents.

— **Keywords:** *Burkholderia*, Cystic fibrosis, Cepacia syndrome.

INTRODUCTION

Burkholderia cepacia complex (Bcc) consists of a group of 24 closely related pathogenic bacterial species which are known for causing opportunistic infections among patients with cystic fibrosis and other vulnerable population¹. They are gram negative, non-lactose fermenting, oxidase positive organisms which are resistant to antimicrobial like polymyxin and aminoglycosides^{1,2}. They are distributed widely in the environment and are commonly isolated from water, soil, and moist environments where they can survive for many months. The efflux pump makes it highly resistant to many antibiotics like carboxypenicillins, polymyxin and aminoglycosides. They are known for surviving in nutrient deficient conditions and can metabolize even antimicrobials as carbon sources³. *Burkholderia cepacia* complex can contaminate sterile aqueous pharmaceutical products like intravenous (iv) drugs and solutions. It can con-

taminate non-sterile pharmaceutical products like pre-operative skin solutions, hand sanitizers, nasal sprays, mouthwash and personal care products. It is a frequent cause for recall of various non-sterile pharmaceutical products¹. *Burkholderia* complex is known for causing several nosocomial outbreaks in hospitals particularly affecting patients with cystic fibrosis and other immune-compromised patients. Its ability to survive in the presence of disinfectants, antimicrobials and biocides used in pharmaceutical products has led to several *Burkholderia* outbreaks in hospitals.

Cepacia syndrome is a clinical condition among patients with *Burkholderia cepacia* infection which was initially documented among children with cystic fibrosis. Patients with cepacia syndrome present with features of necrotizing pneumonia and bacteremia which is associated with sudden deterioration in pulmonary function, fever, leukocytosis and raised inflammatory markers⁴. Among patients with cystic fibrosis, *Burk-*



This work is licensed under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/)

holderia cepacia can also result in asymptomatic carriage and long-term colonization of the respiratory tract^{5,6}. Ceftazidime, meropenem, doxycycline, minocycline, Trimethoprim-sulfamethoxazole and doripenem are effective antibiotics against *Burkholderia* infection. They are resistant to antibiotics like carboxypenicillins, polymyxin and aminoglycosides⁷.

Burkholderia outbreaks have been reported in several health care facilities particularly in ICUs, oncology units and renal failure patients. Studies⁸⁻¹² have reported several sources of Bcc infection like indwelling venous catheter, contaminated water ampules, ultrasound gel, nebulized medications and lipid emulsion stoppers. Bressler et al⁸ have reported that patients requiring dialysis, bronchoscopic procedures, presence of central venous catheter, tracheostomy and recent abdominal surgery were at increased risk of developing *Burkholderia cepacia* bacteremia. Recently, the incidence of *Burkholderia cepacia* infections is increasing due to prolonged and frequent hospital admissions, particularly among the immunocompromised patients in ICU. It can cause bacteremia, urinary tract infections, peritonitis and respiratory tract infections^{13,14}. The number of reported cases is probably lower than the actual number of infections in many hospitals due to difficulty in detection of this organism on routine testing and they are falsely reported as *Pseudomonas* species in several cases¹⁵. Oxidation-fermentation polymyxin bacitracin lactose agar (OFPBL), *Burkholderia cepacia* selective agar (BCSA), and *Pseudomonas cepacia* agar (PCA) are used for selective isolation. It may take 48-72 hours to grow Bcc on these agars^{16,17}. Broth microdilution, agar dilution or Etest MIC are recommended for antibiotic susceptibility testing for Bcc. Species-specific *recA*-based PCR test and Matrix Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) mass spectrometry is used for species identification of Bcc^{18,19}. Cox et al²⁰ concluded that combining MALDI-TOF mass spectrometry with phage amplification is a rapid, sensitive, and reproducibly predictable approach for protein-based bacterial identification and determining antibiotic resistance among Bcc.

There are no randomized controlled trials regarding the treatment of Bcc infection. Treatment is given according to the antibiotic sensitivity on a case by case basis due to lack of studies regarding Bcc infection. Meropenem, doripenem, ceftazidime, trimethoprim-sulfamethoxazole, doxycycline and minocycline are the most effective drugs based on *in vitro* antibiotic sensitivity data²¹. These drugs can be used as first-line therapy or a combination of these drugs can be used in view of increasing resistance^{22,23}. Cochrane systematic review by Horsley et al^{24,25} (conducted in 2012 and 2016) and Regan et al²⁶⁻²⁸ (conducted in 2014, 2016 and 2019) could not identify any relevant study on eradication of Bcc in patients with cystic fibrosis. A systematic review on treatment options in patients with Bcc infection concluded that co-trimoxazole, meropenem, ceftazidime, or piperacillin-tazobactam can be given either as monotherapy or in combination with other antimicrobial agents^{29,30}. The review analyzed 8 cohort studies

or trials and 48 case reports. On analyzing the data, it was found that ceftazidime had a favorable outcome in 77.8% (42/54) patients. 33 patients received monotherapy with ceftazidime while 21 patients received combination therapy with ceftazidime. The combination therapy included ceftazidime along with aminoglycoside, piperacillin-tazobactam, aztreonam and co-trimoxazole. Among patients who received carbapenems, 66.7% (11/15) had a favorable outcome. Monotherapy with meropenem was given to 9 patients, while 6 patients received combination therapy with imipenem and ceftazidime. However, due to insufficient data, the clinical benefit of combination therapy over monotherapy for Bcc infection could not be determined³⁰.

Among patients with cystic fibrosis, exacerbations due to Bcc infections are usually treated with intravenous therapy with a combination of two antimicrobials for 14 -21 days^{31,32}. A study³² comprising 102 patients with cystic fibrosis with acute pulmonary exacerbations due to *Pseudomonas aeruginosa* and/or *B. cepacia complex* concluded that combination of meropenem with tobramycin and ceftazidime with tobramycin improved clinical outcome in these patients with acute pulmonary exacerbations³². Bronchodilators and intensive chest physiotherapy are also recommended for patients with cystic fibrosis and acute pulmonary exacerbations³³. Trimethoprim-sulfamethoxazole, minocycline or doxycycline can be used when oral drugs are preferred.

CASE REPORT

A 23-year-old divorced women of a lower socio-economic background who was working as a receptionist in a private firm presented to the Emergency Department with complaints of fever for 2 days. The patient was apparently well 10 days prior to admission when she started having generalized weakness, decreased appetite and nausea. Her temperature was documented to be around 99°F-100.8°F at that time. Patient took paracetamol (acetaminophen) tablet as she was having myalgia and fever. She did not show in any hospital as her fever subsided after taking paracetamol. However, 2 days prior to presentation patient started having multiple episodes of loose stools and vomiting. She had 3 to 4 episodes of loose stools per day. There was no history of blood in stools or hematemesis. She started having fever ranging from 100°F-102°F. In view of the above symptoms, one day prior to presentation she gave her blood investigations in an outside laboratory. Her hemoglobin was 4.3 g/dl (Normal range: 12.0-15.5 g/dl), total leucocyte count (TLC) was 1.9 x 10⁹/L (Normal range: 4.5 to 11.0 x 10⁹/L) and platelet count was 59 x10⁹/L. However, the patient did not go to any hospital, and she continued taking paracetamol tablets thrice a day for fever. On the day of the presentation, her general condition worsened, the patient became lethargic and drowsy. In view of the worsening of her condition, relatives brought the patient to the Emergency Department of the hospital. On arriving at the emergency department, patient had 1 episode of generalized tonic-clonic seizure.

On examination she had tachypnea (respiratory rate of 26 breaths/min), tachycardia (pulse rate of 138/minute) and blood pressure was unrecordable. Patient was in altered sensorium, however there was no focal neurological deficit. There were no other significant findings on examination. She did not have any enlarged lymph nodes or organomegaly. Her blood sugar was 104 mg/dl. She was started on inotropic supports as her blood pressure remained unrecordable despite giving fluid boluses. Her arterial blood gases showed severe metabolic acidosis with high lactate. Her serum lactate was 16 mmol/L (Normal range: 0.6 to 1.4 mmol/L). Computed tomography (CT) of the head was done which was normal. Her chest x-ray was normal. Ultrasound of the abdomen and pelvis was done and did not show any focus of infection. Her investigations revealed pancytopenia. Her haemoglobin level was 3.1 gm/dL (Normal range: 12.0-15.5 g/dl), red blood cell count (RBC) was $0.88 \times 10^{12}/L$ (Normal range: $3.8-5.8 \times 10^{12}/L$), total leucocyte count (TLC) was $1.9 \times 10^9/L$ (Normal range: 4.5 to $11.0 \times 10^9/L$), platelets $42 \times 10^9/L$ (Normal range: 150 to $400 \times 10^9/L$). Her absolute neutrophil count was 569 cells/ μL . Hence patient was managed as a case of fever with neutropenia and septic shock. Patient was empirically started on meropenem to cover for gram negative infections and Teicoplanin as an agent against methicillin-resistant *Staphylococcus aureus*. The Infectious Diseases Society of America recommends starting an anti-pseudomonal beta-lactam agent (such as cefepime, meropenem, imipenem, or piperacillin-tazobactam) along with an agent active against methicillin-resistant *Staphylococcus aureus* in patients presenting with febrile neutropenia and septic shock. Her serum creatinine was 1.9 mg/dl (Normal range 0.7 to 1.3 mg/dL), blood urea was 54 mg/dl (Normal range 5 to 20 mg/dl), lactate dehydrogenase level (LDH) was 3931 (Normal range: 140-280 U/L). Her total bilirubin was 2.3 mg/dl (Normal range: 0.3-1 mg/dl), direct bilirubin was 0.9 mg/dl (Normal range: 0.1-0.3 mg/dl), aspartate aminotransferase (AST) was 143 U/L (Normal range 4-32 U/L) and alanine aminotransferase (ALT) was 35 U/L (Normal range: 4-33 U/L). Her C-reactive protein was 44 mg/dL (Normal range: less than 3.0 mg/L). Direct coombs test (DCT) and indirect coombs test were negative.

The possibility of dengue hemorrhagic fever/malaria/rickettsial infection was also considered in view of pancytopenia. Blood investigations which were sent to rule out other infectious diseases came negative. Her dengue Ns1 antigen, Dengue IgM, Dengue IgG, Scrub typhus serology, leptospira antigen, leptospira serology, film for malarial parasite, malarial antigen, Weil-Felix test and Widal test were negative. Screening for Human immunodeficiency virus (HIV) was negative. Peripheral smear showed macrocytosis. Mean corpuscular volume (MCV) was 115 fL (Normal range: 80-95 fL). Her Vitamin B12 level was 140 pg/ml (Normal range: 300-950 pg/mL). Folic acid level was 2.85 ng/ml (Normal range: 4-19.9 ng/ml). As she was a vegetarian by diet, a possibility of Vitamin B12 and Folic acid deficiency with Megaloblastic anemia was kept. Corrected reticulocyte count was 0.2% (Normal range: 0.5%-1.5%). Her

pancytopenia was attributed to Vitamin B12/ Folic acid deficiency and sepsis. Elevated LDH level was attributed to hemolysis secondary to megaloblastic anemia^{34,35}. She was transfused packed red blood cells in view of hypotension and low haemoglobin levels. Her procalcitonin level was >100 ng/ml (Normal range: less than 0.25 ng/mL).

Two sets of blood cultures which were sent on admission came positive for *Burkholderia cepacia*. Subculture of the organism was done in blood agar and MacConkey agar. The organism was Gram negative, non-lactose fermenter and oxidase positive. Sugar fermentation test was positive for mannitol, sucrose and sorbitol. Lysine decarboxylase test was positive and the organism was resistant to Polymyxin B. Arginine dihydrolase, gelatin hydrolysis and deoxyribonuclease (DNase) test was negative. Oxidation Fermentation mannitol test was positive. Hence the organism was diagnosed to be *Burkholderia cepacia*. It was sensitive to meropenem, piperacillin-tazobactam, and cefoperazone-sulbactam. It was resistant to amikacin, ampicillin, colistin and polymyxin B. Her urinalysis and urine culture did not show any evidence of urinary tract infection and blood cultures did not show the growth of any other organism.

Her clinical condition gradually improved and her inotropic supports were gradually tapered and stopped on the 4th day of hospital stay. She was started on vitamin B 12 injections and folic acid supplements and meropenem was given for a total of 14 days. Her TLC and platelets gradually improved, and the patient was discharged as her clinical condition became better. On follow-up after 1 month, the patient was asymptomatic and her haemoglobin, TLC, platelets and reticulocyte count were found to be normal. Her peripheral smear, creatinine, Liver function test, LDH, C-reactive protein and procalcitonin levels were normal. Patient was on regular follow-up for 6 months following discharge and she remained asymptomatic. Her hematologic and biochemical parameters were within normal range on follow-up.

DISCUSSION

On reviewing the literature, most cases of Bcc sepsis have been reported in patients who are admitted in hospital with cystic fibrosis, underlying pulmonary disease, patients with HIV or immunocompromised patients and in most cases, it is a hospital acquired infection. Patients requiring hemodialysis, intensive care admission, indwelling catheters and mechanical ventilation are at increased risk of Bcc infection²⁸. Cases among patients without cystic fibrosis have been reported in ICUs due to contaminated intravenous (iv) cannulas, medications or solutions which are being used in the hospital. These patients present with symptoms of respiratory tract infection or necrotizing pneumonia along with features of bacteremia⁴.

Uncommon presentations like endophthalmitis post-ocular surgery or eye trauma, spontaneous bacterial peritonitis in patients with liver cirrhosis, skin, and soft tissue infections among children with chronic

granulomatous disease and vaginitis in a patient with smoldering myeloma has been reported in literature³⁶⁻³⁸. Marioni et al³⁹ reported a case of cervical necrotizing fasciitis by Bcc in an immuno-competent patient which was treated by surgical debridement and 2 weeks of IV cefepime according to antibiotic sensitivity. Spontaneous bacterial peritonitis with Bcc has been reported in literature probably due to the higher degree of neutrophil dysfunction among patients with alcoholic cirrhosis. Successful treatment using combinations of meropenem with ciprofloxacin and tobramycin has been reported, and doripenem has therapeutic potential against spontaneous bacterial peritonitis due to Bcc⁴⁰. Gautam et al⁴¹ reported *Burkholderia cenocepacia* sepsis in a patient with mitral stenosis which was treated using Ceftazidime 2 grams twice daily. Case report of a patient with smoldering myeloma and *Burkholderia cenocepacia* vaginitis was treated with piperacillin-tazobactam for 4 weeks following which her symptoms resolved and repeat vaginal swab cultures were negative³⁸. In a study by Mann et al⁴², *Burkholderia* bacteremia has been reported among patients with solid tumors and hematological malignancies. To our knowledge, this is the first reported case of Bcc sepsis in a patient with underlying megaloblastic anemia. Patients with megaloblastic anemia are susceptible to various infections due to impaired leucocyte function which results in impaired intracellular killing of ingested bacteria by neutrophils and macrophages⁴³⁻⁴⁵.

In our patient, there has been no history of previous hospital admissions, IV cannula or catheter insertion prior to presentation. As the initial blood culture sent from the Emergency Department was positive for *Burkholderia cepacia*, she acquired this infection from the community. Unlike most of the reported cases of *Burkholderia* infection, our patient did not have any respiratory symptoms and she presented with features of septic shock and generalized tonic clonic seizures. However, regarding the source of infection, we did not get any history regarding usage of contaminated pharmaceutical products, solutions, or contaminated water in our patient.

Conclusions

Bcc is known for causing hospital acquired infections in immune compromised patients and patients with Cystic fibrosis. As reported in this case, patients can acquire Bcc infection from the community and they can present without any respiratory symptoms. Bcc infection and cepacia syndrome should be considered in patients who are at increased risk of developing these infections. Identification of the organism and antibiotic according to the culture sensitivity report is important as this organism is inherently resistant to many antibiotics.

CONFLICT OF INTERESTS:

The authors declare that they have no conflicts of interest.

FUNDING:

No funding was received for conducting this study.

INFORMED CONSENT:

Patient signed the informed consent.

REFERENCES

1. Tavares M, Kozak M, Balola A, Sá-Correia I. Burkholderia cepacia Complex Bacteria: a Feared Contamination Risk in Water-Based Pharmaceutical Products. Clin Microbiol Rev 2020; 33: e00139-19.
2. Wuthiekanun V, Smith MD, Dance DA, Walsh AL, Pitt TL, White NJ. Biochemical characteristics of clinical and environmental isolates of Burkholderia pseudomallei. J Med Microbiol 1996; 45: 408-412.
3. Sfeir MM. Burkholderia cepacia complex infections: More complex than the bacterium name suggest. J Infect 2018; 77: 166-170.
4. Sousa SA, Ramos CG, Leitão JH. Burkholderia cepacia Complex: Emerging Multihost Pathogens Equipped with a Wide Range of Virulence Factors and Determinants. Int J Microbiol 2011; 2011: 607575.
5. De Boeck K, Malfroot A, Van Schil L, Lebecque P, Knoop C, Govan JR, Doherty C, Laevens S, Vandamme P; Belgian Burkholderia cepacia Study Group. Epidemiology of Burkholderia cepacia complex colonisation in cystic fibrosis patients. Eur Respir J 2004; 23: 851-856.
6. Ledson MJ, Gallagher MJ, Jackson M, Hart CA, Walshaw MJ. Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre. Thorax 2002; 57: 142-145.
7. Rhodes KA, Schweizer HP. Antibiotic Resistance in Burkholderia Species. Drug Resist Updat 2016; 28: 82-90.
8. Bressler AM, Kaye KS, LiPuma JJ, Alexander BD, Moore CM, Reller LB, Woods CW. Risk factors for Burkholderia cepacia complex bacteremia among intensive care unit patients without cystic fibrosis: a case-control study. Infect Control Hosp Epidemiol 2007; 28: 951-958.
9. Nasser RM, Rahi AC, Haddad MF, Daoud Z, Irani-Hakime N, Almawi WY. Outbreak of Burkholderia cepacia bacteremia traced to contaminated hospital water used for dilution of an alcohol skin antiseptic. Infect Control Hosp Epidemiol 2004; 25: 231-239.
10. Hutchinson J, Runge W, Mulvey M, Norris G, Yetman M, Valkova N, Villemur R, Lepine F. Burkholderia cepacia infections associated with intrinsically contaminated ultrasound gel: the role of microbial degradation of parabens. Infect Control Hosp Epidemiol 2004; 25: 291-296.
11. Balkhy HH, Cunningham G, Francis C, Almuneef MA, Stevens G, Akkad N, Elgammal A, Alassiri A, Furukawa E, Chew FK, Sobh M, Daniel D, Poff G, Memish ZA. A National Guard outbreak of Burkholderia cepacia infection and colonization secondary to intrinsic contamination of albuterol nebulization solution. Am J Infect Control 2005; 33: 182-188.
12. Doit C, Loukil C, Simon AM, Ferroni A, Fontan JE, Bonacorsi S, Bidet P, Jarlier V, Aujard Y, Beaufilets F, Bingen E. Outbreak of Burkholderia cepacia bacteremia in a pediatric hospital due to contamination of lipid emulsion stoppers. J Clin Microbiol 2004 ;42: 2227-2230.
13. Hauser N, Orsini J. Cepacia Syndrome in a Non-Cystic Fibrosis Patient. Case Rep Infect Dis 2015; 2015: 537627.
14. Gangaram U, Ramya T, Jithendra K, Mohan DR. Burkholderia cepacia an emerging cause of septicemia, in an intensive care unit from a tertiary care hospital, Nellore, India. International Journal of Advances in Medicine 2020; 7: 413-417.
15. McMenamin JD, Zacccone TM, Coenye T, Vandamme P, Li Puma JJ. Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers: an analysis of 1,051 recent sputum isolates. Chest 2000; 117: 1661-1665.

16. Henry D, Campbell M, McGimpsey C, Clarke A, Loudon L, Burns JL, Roe MH, Vandamme P, Speert D. Comparison of isolation media for recovery of *Burkholderia cepacia* complex from respiratory secretions of patients with cystic fibrosis. *J Clin Microbiol* 1999; 37: 1004-1007.
17. Glass MB, Wilkins PP, Hoffmaster AR, Beesley CA. Comparison of Four Selective Media for the Isolation of *Burkholderia mallei* and *Burkholderia pseudomallei*. *Am J Trop Med Hyg* 2009; 80: 1023-1028.
18. Chan CH, Stead DE, Coutts RH. Development of a species-specific *recA*-based PCR test for *Burkholderia fungorum*. *FEMS Microbiol Lett* 2003; 224: 133-138.
19. Fehlberg LC, Andrade LH, Assis DM, Pereira RH, Gales AC, Marques EA. Performance of MALDI-ToF MS for species identification of *Burkholderia cepacia* complex clinical isolates. *Diagn Microbiol Infect Dis* 2013; 77: 126-128.
20. Cox CR, Saichek NR, Schweizer HP, Voorhees KJ. Rapid *Burkholderia pseudomallei* identification and antibiotic resistance determination by bacteriophage amplification and MALDI-TOF MS. *Bacteriophage* 2014; 4: e29011.
21. Tseng SP, Tsai WC, Liang CY, Lin YS, Huang JW, Chang CY, Tyan YC, Lu PL. The contribution of antibiotic resistance mechanisms in clinical *Burkholderia cepacia* complex isolates: an emphasis on efflux pump activity. *PLoS One* 2014; 9: e104986.
22. Tamma PD, Fan Y, Bergman Y, Sick-Samuels AC, Hsu AJ, Timp W, Simner PJ, Prokesch BC, Greenberg DE. Successful Treatment of Persistent *Burkholderia cepacia* Complex Bacteremia with Ceftazidime-Avibactam. *Antimicrob Agents Chemother* 2018; 62: e02213-17.
23. Abbott FK, Milne KE, Stead DA, Gould IM. Combination antimicrobial susceptibility testing of *Burkholderia cepacia* complex: significance of species. *Int J Antimicrob Agents* 2016; 48: 521-527.
24. Horsley A, Jones AM. Antibiotic treatment for *Burkholderia cepacia* complex in people with cystic fibrosis experiencing a pulmonary exacerbation. *Cochrane Database Syst Rev* 2012; 10: CD009529.
25. Horsley A, Jones AM, Lord R. Antibiotic treatment for *Burkholderia cepacia* complex in people with cystic fibrosis experiencing a pulmonary exacerbation. *Cochrane Database Syst Rev* 2016; 1: CD009529.
26. Regan KH, Bhatt J. Eradication therapy for *Burkholderia cepacia* complex in people with cystic fibrosis. *Cochrane Database Syst Rev* 2014; 10: CD009876.
27. Regan KH, Bhatt J. Eradication therapy for *Burkholderia cepacia* complex in people with cystic fibrosis. *Cochrane Database Syst Rev* 2016; 11: CD009876.
28. Regan KH, Bhatt J. Eradication therapy for *Burkholderia cepacia* complex in people with cystic fibrosis. *Cochrane Database Syst Rev* 2019; 4: CD009876.
29. *Burkholderia cepacia* complex - Infectious Disease and Antimicrobial Agents. Accessed February 3, 2022. <http://www.antimicrobe.org/b19.asp>
30. Avgeri SG, Matthaiou DK, Dimopoulos G, Grammatikos AP, Falagas ME. Therapeutic options for *Burkholderia cepacia* infections beyond co-trimoxazole: a systematic review of the clinical evidence. *Int J Antimicrob Agents* 2009; 33: 394-404.
31. Chernish RN, Aaron SD. Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis. *Curr Opin Pulm Med* 2003; 9: 509-515.
32. Blumer JL, Saiman L, Konstan MW, Melnick D. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. *Chest* 2005; 128: 2336-2346.
33. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. *N Engl J Med* 1996; 335: 179-188. Erratum in: *N Engl J Med* 1996; 335: 1167.
34. Kinra P. Prevalence of Haemolysis in Peripheral Blood Smear in Cases of Megaloblastic Anemia. *Med J Armed Forces India* 2006; 62: 401.
35. Socha DS, DeSouza SI, Flagg A, Sekeres M, Rogers HJ. Severe megaloblastic anemia: Vitamin deficiency and other causes. *Cleve Clin J Med* 2020; 87: 153-164.
36. Agochukwu NQ, Rastinehad AR, Richter LA, Barak S, Zerbe CS, Holland SM, Pinto PA. Prostatic abscess in a pediatric patient with chronic granulomatous disease: report of a unique case and review of the literature. *J Pediatr Surg* 2012; 47: 400-403.
37. Loertzer H, Höhne SO, Finke R, Fornara P. Intramural bladder-wall abscess: a late complication arising after a urethro-cystoscopy? *Pediatr Surg Int* 2005; 21: 323-325.
38. Petrucca A, Cipriani P, Sessa R, Teggi A, Pustorino R, Santapaola D, Nicoletti M. *Burkholderia cenocepacia* vaginal infection in patient with smoldering myeloma and chronic hepatitis C. *Emerg Infect Dis* 2004; 10: 1957-1959.
39. Marioni G, Rinaldi R, Ottaviano G, Marchese-Ragona R, Savastano M, Staffieri A. Cervical necrotizing fasciitis: a novel clinical presentation of *Burkholderia cepacia* infection. *J Infect* 2006; 53: e219-222.
40. Taneja S, Kumar P, Gautam V, Duseja A, Singh V, Dhi-man RK, Chawla Y. Spontaneous Bacterial Peritonitis by *Burkholderia cepacia* Complex: A Rare, Difficult to Treat Infection in Decompensated Cirrhotic Patients. *J Clin Exp Hepatol* 2017; 7: 102-106.
41. Gautam V, Ray P, Das A, Vandamme P, Malhotra P, Varma S, Vijayvergiya R, Mandal J, Garg N. Two cases of *Burkholderia cenocepacia* in septicemic patients. *Jpn J Infect Dis* 2008; 61: 133-134.
42. Mann T, Ben-David D, Zlotkin A, Shachar D, Keller N, Toren A, Nagler A, Smollan G, Barzilai A, Rahav G. An outbreak of *Burkholderia cenocepacia* bacteremia in immunocompromised oncology patients. *Infection* 2010; 38: 187-194.
43. Kaplan SS, Basford RE. Effect of vitamin B12 and folic acid deficiencies on neutrophil function. *Blood* 1976; 47: 801-805.
44. Siddiqui B, Rabindranath D, Faridi SH, Khan AA, Haiyat S, Eswaran R. Megaloblastic anemia: A common but often neglected cause of pyrexia of unknown origin. *J Transl Int Med* 2015; 3: 64-67.
45. Gomber S, Kela K, Dhingra N. Clinico-hematological profile of megaloblastic anemia. *Indian Pediatr* 1998; 35: 55-58.